Elan Shareholder Vote Indicates Lack Of Faith In Management’s Decisions
This article was originally published in The Pink Sheet Daily
Executive Summary
The Irish company’s investors voted against its plans to transform the company, but have left its suitor, Royalty Pharma, with few options to continue pursuing the bid.
You may also be interested in...
Elan’s Martin Aims To Set The Record Straight About Recent Buying Spree
Changes at the Irish company have sparked a swath of media speculation and analyst interest. Elan CEO Kelly Martin used a recent fireside chat in New York to paint a clearer picture of what is going on at the company and the rationale behind its recently proposed M&A.
Elan Makes A $1 Billion Theravance Royalty Play; What Will Investors Say?
The Irish company, fighting a takeover offer from Royalty Pharma, has made the first of several planned deals: Elan will pay $1 billion to Theravance in exchange for a 21% interest in future royalty payments from four respiratory programs partnered with GlaxoSmithKline. Theravance shares soared on the news.
GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.